With 22.62 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.21 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $47.69 whereas the lowest price it dropped to was $47.57. The 52-week range on TRML shows that it touched its highest point at $30.59 and its lowest point at $11.56 during that stretch. It currently has a 1-year price target of $48.61. Beta for the stock currently stands at 2.05.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TRML was up-trending over the past week, with a rise of 102.12%, but this was up by 129.92% over a month. Three-month performance surged to 152.33% while six-month performance rose 225.19%. The stock gained 134.91% in the past year, while it has gained 197.75% so far this year. A look at the trailing 12-month EPS for TRML yields -3.44 with Next year EPS estimates of -4.07. For the next quarter, that number is -0.97. This implies an EPS growth rate of -21.92% for this year and -15.54% for next year. EPS is expected to decline by -15.25% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 8.04%.
Float and Shares Shorts:
At present, 25.69 million TRML shares are outstanding with a float of 16.64 million shares on hand for trading. On 2025-08-15, short shares totaled 2.5 million, which was 975.0 higher than short shares on 1752537600. In addition to Dr. Sandeep C. Kulkarni M.D. as the firm’s Co-Founder, CEO & Director, Mr. Ryan Robinson CPA serves as its CFO & Treasurer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, TRML reported revenue of $0.0 and operating income of -$25974000.0. The EBITDA in the recently reported quarter was -$25962000.0 and diluted EPS was -$0.9.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With TRML analysts setting a high price target of 65.0 and a low target of 35.0, the average target price over the next 12 months is 48.61111. Based on these targets, TRML could surge 36.44% to reach the target high and fall by -26.53% to reach the target low. Reaching the average price target will result in a growth of 2.04% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.72321 being high and -$3.46943 being low. For TRML, this leads to a yearly average estimate of -$2.89765. The surprise factor in the prior quarter was -$0.94. Based on analyst estimates, the high estimate for the next quarter is -$0.94 and the low estimate is -$1.21. The average estimate for the next quarter is thus -$1.02.
